AcelRx

$0.49 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About AcelRx

AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.

Stock Analysis

last close $0.51
1-mo return -9.1%
3-mo return -48.6%
avg daily vol. 1.26M
52-week high 2.94
52-week low 0.46
market cap. $76M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $4M
inst own. 17.2%
baraka

Subscribe now for daily local and international financial news

Subscribe